Lastly, given the fact that CD36 can be a therapeutic target of interest in the treatment of the common co-morbidities of cancer patients, such as atherosclerosis and diabetes, anti-CD36 therapy also has the potential to concurrently correct these systemic metabolic dysfunctions. This evidence concerns the gene CD36 and atherosclerosis.